Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective

Author:

Ludwig Heinz1,Beksac Meral2,Bladé Joan3,Cavenagh Jamie4,Cavo Michele5,Delforge Michel6,Dimopoulos Meletios7,Drach Johannes8,Einsele Hermann9,Facon Thierry10,Goldschmidt Hartmut11,Harousseau Jean-Luc12,Hess Urs13,Kropff Martin14,Leal da Costa Fernando15,Louw Vernon16,Magen-Nativ Hila17,Mendeleeva Larisa18,Nahi Hareth19,Plesner Torben20,San-Miguel Jesús21,Sonneveld Pieter22,Udvardy Miklos23,Sondergeld Pia24,Palumbo Antonio25

Affiliation:

1. a Wilhelminenspital, Vienna, Austria;

2. b Ankara University, Department of Haematology, Ankara, Turkey;

3. c Department of Hematology, Hospital Clinic, Barcelona, Spain;

4. d Department of Haematology, St Bartholomew's Hospital, London, United Kingdom;

5. e Institute of Hematology and Medical Oncology, Seragnoli, Bologna, Italy;

6. f Department of Hematology, University Hospital Leuven, Leuven, Belgium;

7. g Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece;

8. h Department of Oncology, University Clinic Vienna, Vienna, Austria;

9. i Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany;

10. j Service d'Hématologie, Centre Hospitalier Universitaire (CHU), Lille, France;

11. k Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;

12. l Centre René Gauducheau Nantes, Nantes, France;

13. m Division of Oncology/Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland;

14. n Department of Medicine/Hematology and Oncology, University of Münster, Münster, Germany;

15. o Portuguese Institute of Oncology, Lisbon, Portugal;

16. p Division Clinical Haematology, Department of Internal Medicine, University of the Free State, Bloemfontein, South Africa;

17. q Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah-Tiqva, Israel;

18. r Hematology Scientific Center, Russian Academy of Medical Sciences, Moscow, Russia;

19. s Department of Hematology, Karolinska University Hospital, Huddinge, Stockholm, Sweden;

20. t Department of Haematology, IRS-CSFU, University of Southern Denmark, Vejle Hospital, Vejle, Denmark;

21. u Servicio de Hematología, Hospital Universitario de Salamanca, and CIC, IBMCC (USAL-CSIC), Salamanca, Spain;

22. v Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands;

23. w Institute of Medicine, Medical and Health Science Centre, Debrecen, Hungary;

24. x Ammonite Systems Ltd., Faringdon, United Kingdom;

25. y Divisione di Ematologia dell'Universití di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy

Abstract

Abstract The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.

Funder

Janssen Pharmaceutical Companies of Johnson & Johnson in Europe

Middle East, and Africa

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3